Our research may suggest a possible therapeutic use of PD‐1/PD‐L1 inhibition in Zollinger Ellison syndrome patients with either primary gastrinomas or other gastrin‐producing tumors.57, 58. Here, CD274 is linked to gastrin-producing neuroendocrine tumor.